Doctors find rare clotting disorder combo in man facing amputation
Doctors discovered a rare combination of blood clotting disorders — acquired hemophilia A alongside an inherited disorder called Factor…
Articles by Steve Bryson, PhD
Novo Nordisk asks FDA to approve hem A injection therapy Mim8
Novo Nordisk has submitted an application to the U.S. Food and Drug Administration seeking approval to market Mim8…
Standard or low-dose rituximab effective for acquired hemophilia A
Nearly all adults with acquired hemophilia A (AHA) safely achieved complete remission with either standard or low doses of…
Switching to Elocta shown to improve bleed control in real world
Switching from standard half-life factor replacement therapies to the extended half-life treatment Elocta (efmoroctocog alfa) improves bleed control among people…
Patient in Germany gets hemophilia B gene therapy Hemgenix
The first hemophilia B patient in Germany has received the gene therapy Hemgenix (etranacogene dezaparvovec), according to CSL…
Safety, efficacy of Hemlibra for Hem A confirmed in review study
Hemlibra (emicizumab-KXWH) safely reduces bleeding episodes in people with hemophilia A without inhibitors, resulting in a high rate…
Directly switching from Hemlibra to investigational Mim8 well tolerated
Directly switching from Hemlibra (emicizumab) to Novo Nordisk‘s investigational Mim8 (denecimig) was well tolerated in adults and…
Stabilizing bonds in clotting protein may thwart hemophilia A inhibitors
The blood-clotting protein factor VIII (FVIII) that’s missing or faulty in people with hemophilia A is flexible and adopts…
Sobi, Sanofi make new donation of clotting factor to WFH aid program
Sobi and Sanofi’s philanthropic organization, Foundation S, have announced an additional donation of up to 100 million international…
Hemophilia children have problems with dynamic balance, falls: Study
Children with hemophilia have problems with dynamic balance — the ability to maintain balance while moving — and an…